Celcuity Inc. (NASDAQ:CELC) Shares Purchased by Braidwell LP

Braidwell LP grew its holdings in shares of Celcuity Inc. (NASDAQ:CELC) by 71.2% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 884,306 shares of the company’s stock after purchasing an additional 367,663 shares during the period. Braidwell LP’s holdings in Celcuity were worth $13,185,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the business. nVerses Capital LLC bought a new stake in shares of Celcuity during the 3rd quarter valued at about $33,000. Prospera Private Wealth LLC acquired a new position in Celcuity in the third quarter valued at approximately $35,000. Values First Advisors Inc. acquired a new stake in shares of Celcuity during the 3rd quarter worth approximately $86,000. Quest Partners LLC raised its position in shares of Celcuity by 31.3% during the 2nd quarter. Quest Partners LLC now owns 5,788 shares of the company’s stock worth $95,000 after purchasing an additional 1,379 shares during the period. Finally, SG Americas Securities LLC bought a new stake in shares of Celcuity in the 3rd quarter worth approximately $119,000. 63.33% of the stock is currently owned by institutional investors.

Celcuity Stock Performance

Shares of CELC opened at $12.85 on Friday. The company has a current ratio of 10.35, a quick ratio of 10.36 and a debt-to-equity ratio of 0.65. The firm has a 50-day moving average price of $14.74 and a 200 day moving average price of $15.77. Celcuity Inc. has a 52-week low of $11.51 and a 52-week high of $22.19.

Analyst Ratings Changes

Several brokerages have weighed in on CELC. Needham & Company LLC reaffirmed a “buy” rating and issued a $23.00 target price on shares of Celcuity in a research report on Friday, November 15th. Stifel Nicolaus lifted their price objective on shares of Celcuity from $39.00 to $42.00 and gave the company a “buy” rating in a research report on Monday, October 7th. Lifesci Capital began coverage on shares of Celcuity in a research report on Monday, August 26th. They issued an “outperform” rating and a $27.00 target price for the company. Finally, HC Wainwright reaffirmed a “buy” rating and set a $27.00 price target on shares of Celcuity in a report on Friday, November 15th. Six research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $29.17.

About Celcuity

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.